Nath Bio-Genes (India) Ltd (NATHBIOGEN) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Nath Bio-Genes (India) Ltd on NSE and BSE, with an AI summary of each filing.
Proceedings of AGM and Scrutinizers report for AGM held on 24th September 2026
Annual General Meeting · 24 Sept 2026, 10:49 pm
Record Date
Dividend · 05 Sept 2026, 10:15 pm
Nath Bio-Genes Fixes Record Date for AGM Voting and Dividend Eligibility Nath Bio-Genes (India) Limited has scheduled its 33rd Annual General Meeting for 24th Sep'26 via video conferencing. Pursuant to Regulation 42 of SEBI LODR Regulations, the company fixed Friday, 11th Sep'26, as the Record Date to determine shareholder eligibility for voting at the AGM and entitlement to dividend.
Intimation for record date
Dividend · 04 Sept 2026, 10:37 pm
Nath Bio-Genes Fixes Record Date for AGM and Dividend Eligibility Nath Bio-Genes (India) Limited has scheduled its 33rd Annual General Meeting for 24th Sep'26 via Video Conferencing/OAVM. The company has fixed Friday, 11th Sep'26, as the cut-off date to determine shareholder eligibility for voting at the AGM as well as entitlement to dividend payouts.
Record Date for the AGM and Dividend
Dividend · 01 Sept 2026, 11:06 pm
Notice of Annual General Meeting and Annual Report
Others (Uncategorized) · 01 Sept 2026, 11:04 pm
Notice of Annual General Meeting and Annual Report 2025-26
Annual General Meeting · 01 Sept 2026, 10:54 pm
Intimation of Initiation of Forensic Audit
Others (Uncategorized) · 06 Aug 2026, 8:38 pm
Nath Bio-Genes Under Forensic Audit Ordered by SEBI On 05 Aug'26, Nath Bio-Genes received communication from SEBI initiating a forensic audit of the company. SEBI has appointed CNK & Associates LLP as the forensic auditor to examine the company's books of account and records for the financial years 2020-21 to 2025-26. The company stated it is extending full cooperation to the auditor but is unable to comment on the potential impact pending the audit's completion. This action raises significant corporate governance concerns and potential stock price volatility.
Investor Presentation on Unaudited Financial Results as of 30th June 2026
Investor Presentation · 30 Jul 2026, 6:15 pm
Nath Bio-Genes Reports Strong Q1FY27 Revenue and EBITDA Growth Nath Bio-Genes reported robust Q1FY27 results, with revenue growing 15% YoY to ₹3,228 Mn and EBITDA up 17% YoY to ₹351 Mn. PAT increased by 12% YoY to ₹327 Mn. Strong QoQ volume growth was seen in Maize (44%) and Paddy (19%), which also saw a 34% value increase from premium products. The revenue mix shifted slightly, with Paddy's contribution rising to 35% from 30% YoY, while Cotton's share decreased to 34% from 40%. Gross margin contracted by 100 bps to 50%.
Outcome of Board Meeting: Unaudited Financial results as of 30th June 2026.
Financial Result · 29 Jul 2026, 9:46 pm
Nath Bio-Genes (India) Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) ■ Revenue: 32,840 (+15.8% YoY | +536.5% QoQ) ■ EBITDA: 3,515 (+20.0% YoY | +685.1% QoQ) ■ EBITDA Margin (%): 10.7 (+38 bps YoY | +203 bps QoQ) ■ PAT: 3,226 (+14.1% YoY | Loss to Profit QoQ) ■ EPS (INR): 17.0 (+14.1% YoY)
Nath Bio-Genes (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2026 ,inter alia, to consider and approve Unaudited financial ....
Intimation · 29 Jul 2026, 5:30 am
Nath Bio-Genes Board Meeting on Jul 29, '26 to Approve Q1 FY27 Results Nath Bio-Genes (India) Ltd. scheduled a Board of Directors meeting on 29th Jul '26 to consider and approve its unaudited standalone and consolidated financial results for the quarter ended 30th Jun '26. In connection with this, the company's trading window for insiders has been closed since 30th Jun '26. The trading window will reopen on 01st Aug '26, which is 48 hours after the declaration of the financial results. The stock codes are BSE: 537291 and NSE: NATHBIOGEN.
Earning Call Transcript held on 05th May 2026
Transcript · 11 May 2026, 10:21 pm
Audio Transcript of Concall held on 05th May 2026.
Audio / Video · 11 May 2026, 10:14 pm
Nath Bio-Genes Concall Audio for Q4FY26 Results Available Nath Bio-Genes (I) Ltd. has released the audio recording of its conference call held on 05th May'26. The call discussed the audited financial results for the quarter and year ended 31st Mar'26. The recording is accessible on the company's website, providing investors with direct insights into management's commentary on the Q4FY26 performance and outlook.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Others (Uncategorized) · 11 May 2026, 9:39 pm
Nath Bio-Genes Confirms It Is Not a Large Corporate Nath Bio-Genes (India) Ltd. confirmed it does not meet SEBI's criteria for a "Large Corporate" as of 31st Mar'26. The company stated it has no listed debt securities, outstanding long-term borrowings are below the Rs. 1,000 crore threshold, and its credit rating is not AA or above. The annexure reveals NIL outstanding long-term borrowings and a BBB+ credit rating from India Ratings and Research. This status exempts the company from SEBI's mandatory bond market borrowing requirements for Large Corporates.
Investor Presentation on Financial Results as on 31st March 2026
Investor Presentation · 04 May 2026, 10:51 pm
Nath Bio-Genes Q4 & FY26: Revenue Grows 19% YoY but Margins Contract Nath Bio-Genes reported a 19% YoY revenue increase to ₹4,316 Mn for FY26, driven by strong value growth in Maize (+78%), Paddy (+37%), and Cotton (+28%). International expansion contributed ₹15 crores from Uzbekistan. However, profitability was pressured as Gross Margin contracted to 56% from 63% and EBITDA margin fell to 12% from 14% YoY. EBITDA remained flat at ₹525 Mn. Consequently, PAT declined by 8% to ₹384 Mn, though EPS grew 6% to ₹23.42. The Cotton-Paddy portfolio share increased to 58%.
Outcome of Board Meeting held on 04th May 2026
Outcome · 04 May 2026, 10:44 pm
Nath Bio-Genes (I) Ltd. - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Lakhs) ■ Revenue: 5159 (-0.7% YoY | -21.8% QoQ) ■ EBITDA: 574 (+1288.4% YoY | -8.4% QoQ) ■ EBITDA Margin (%): 11.1 (+1032 bps YoY | +163 bps QoQ) ■ PAT: -151 (Profit to Loss YoY | Profit to Loss QoQ) ■ EPS (INR): -0.79 (Profit to Loss YoY | Profit to Loss QoQ)
Audited Financial Results as on 31st March 2026.
Financial Result · 04 May 2026, 10:37 pm
Nath Bio-Genes (I) Ltd. - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Lakh) ■ Revenue: 5159 (-0.7% YoY | -21.8% QoQ) ■ EBITDA: 574 (+1288.4% YoY | -8.4% QoQ) ■ EBITDA Margin (%): 11.1 (+1032 bps YoY | +163 bps QoQ) ■ PAT: -151 (Profit to Loss YoY | Profit to Loss QoQ) ■ EPS (INR): -0.79 (Profit to Loss YoY | Profit to Loss QoQ)
Intimation for Earning Conference Call to be held on Tuesday, 05th May 2026 at 04:00 PM.
Intimation · 05 May 2026, 4:00 pm
Nath Bio-Genes Schedules Q4 & FY26 Earnings Conference Call Nath Bio-Genes (I) Ltd. has scheduled its Q4 & FY26 earnings conference call for Tue, 05th May'26, at 04:00 PM IST. Key management, including Managing Director Mr. Satish Kagliwal and CFO Mr. Amol Gupta, will be present. The event is hosted by Go India Advisors. The purpose is to discuss the company's financial results and performance for the quarter and fiscal year ending in 2026. The call is a key event for investors to gain insights into the company's outlook.
Nath Bio-Genes (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/05/2026 ,inter alia, to consider and approve Financial Results as ....
Intimation · 04 May 2026, 5:30 am
Nath Bio-Genes Board Meeting to Consider Q4FY26 Results and Dividend Nath Bio-Genes (I) Ltd. has scheduled a Board of Directors meeting on 04th May'26 to consider and approve its audited standalone and consolidated financial results for the fourth quarter and full year ended 31st Mar'26. The board will also consider a dividend recommendation for the financial year 2025-26. The trading window for insiders has been closed since 31st Mar'26 and will reopen on 06th May'26, post the announcement of the financial results.
Investor Presentation of Financial Results as on 31st December 2025
Investor Presentation · 01 Feb 2026, 1:11 am
Nath Bio-Genes Q3FY26 Revenue Jumps 79% YoY on Strong Crop Performance Nath Bio-Genes reported robust Q3FY26 results, with revenue increasing 79% YoY to ₹660 Mn and PAT up 67% to ₹45 Mn. However, EBITDA margin contracted to 13% from 20% last year. For 9MFY26, revenue grew 23% YoY to ₹3,859 Mn, though EBITDA declined 2% to ₹499 Mn. Strong growth was seen in Maize (value +141.98% YoY), Vegetable Seeds (+52.08%), and Cotton (+25.26%). Strategic focus remains on diversification beyond cotton, growing high-margin products, and expanding international presence through its Uzbekistan joint venture.
Issue of Duplicate Share Certificate
Others (Uncategorized) · 31 Jan 2026, 9:54 pm
Nath Bio-Genes Issues Duplicate Share Certificate to Shareholder Nath Bio-Genes (I) Ltd. announced on 31 Jan'26 the issuance of a duplicate share certificate to shareholder K. Sunitha (Folio No. 0007420). The new certificate (No. 9223) replaces the original (No. 7520), which was reported lost or misplaced. The duplicate certificate represents 132 shares with distinctive numbers from 1388735 to 1388866. This action is compliant with SEBI's Regulation 39(3) and was intimated by the company's Registrar and Share Transfer Agent, Bigshare Services Private Limited.
Financial Results as on 31st December 2025.
Financial Result · 31 Jan 2026, 9:29 pm
Nath Bio-Genes Reports Robust Q3FY26 Standalone Profit Growth Nath Bio-Genes reported a strong standalone performance for Q3FY26, with Net Profit surging 172% YoY to ₹723.08 lakh. Revenue from operations grew 79% YoY to ₹6,596.11 lakh. On a QoQ basis, Net Profit increased by 72% from ₹420.09 lakh. For the nine months ended 31st Dec'25, Net Profit was up 13% YoY to ₹4,463.77 lakh. The Basic EPS for Q3 stood at ₹3.80, up from ₹1.40 in Q3FY25. The auditor's report included a qualified opinion regarding the unassessed impact of new Labour Codes.
Nath Bio-Genes (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2026 ,inter alia, to consider and approve Financial Results as ....
Intimation · 31 Jan 2026, 5:30 am
Nath Bio-Genes to Announce Q3FY26 Results on 31-Jan-26 Nath Bio-Genes' Board of Directors will meet on 31 Jan'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended 31 Dec'25. In accordance with insider trading regulations, the company has closed its trading window from 31 Dec'25 until 03 Feb'26.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Tapovan Paper and Board Mills Ltd & Others
Acquisition/ Disposal of Shares · 13 Jan 2026, 11:11 pm
Tapovan Paper Acquires 0.40% Stake in Nath Bio-Genes via Amalgamation Tapovan Paper and Board Mills has acquired 75,645 equity shares, representing 0.40% of Nath Bio-Genes (India) Limited's paid-up capital. The acquisition, effective 9-Jan-26, is part of a sanctioned Scheme of Amalgamation. This transaction involved the transfer of shares from Prabha Farms Private Limited and Paresh Farms Private Limited. The transfer occurred amongst existing promoter group entities and does not result in any change to the aggregate promoter and promoter group shareholding, which remains at 45.60%.
Earning Call Transcript
Transcript · 18 Nov 2025, 10:46 pm
Investor Presentation on financial results as on 30th September 2025.
Investor Presentation · 14 Nov 2025, 4:02 pm